D.E. Shaw & Co
MYGN icon

D.E. Shaw & Co’s Myriad Genetics MYGN Stock Holding History

D.E. Shaw & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2M Sell
4,499,724
-5,469
-0.1% -$28.5K 0.01% 1139
2025
Q4 		$27.7M Sell
4,505,193
-53,943
-1% -$391K 0.02% 1034
2025
Q3 		$33M Buy
4,559,136
+47,639
+1% +$283K 0.02% 874
2025
Q2 		$24M Buy
4,511,497
+1,988,879
+79% +$11.7M 0.02% 927
2025
Q1 		$22.4M Buy
2,522,618
+702,804
+39% +$8.44M 0.02% 880
2024
Q4 		$24.9M Buy
1,819,814
+668,429
+58% +$12.3M 0.02% 905
2024
Q3 		$31.5M Buy
1,151,385
+24,638
+2% +$667K 0.03% 731
2024
Q2 		$27.6M Sell
1,126,747
-139,366
-11% -$3.06M 0.03% 724
2024
Q1 		$27M Sell
1,266,113
-535,193
-30% -$11.5M 0.02% 762
2023
Q4 		$34.5M Sell
1,801,306
-376,619
-17% -$6.52M 0.03% 620
2023
Q3 		$34.9M Buy
2,177,925
+150,903
+7% +$2.87M 0.04% 571
2023
Q2 		$47M Buy
2,027,022
+44,697
+2% +$975K 0.05% 458
2023
Q1 		$46M Buy
1,982,325
+125,025
+7% +$2.54M 0.05% 455
2022
Q4 		$26.9M Buy
1,857,300
+100,834
+6% +$1.88M 0.03% 731
2022
Q3 		$33.5M Sell
1,756,466
-284,394
-14% -$6.53M 0.04% 569
2022
Q2 		$37.1M Buy
2,040,860
+154,286
+8% +$3.2M 0.04% 532
2022
Q1 		$47.5M Sell
1,886,574
-21,030
-1% -$538K 0.04% 513
2021
Q4 		$52.6M Sell
1,907,604
-101,258
-5% -$2.93M 0.04% 518
2021
Q3 		$64.9M Sell
2,008,862
-233,807
-10% -$7.76M 0.06% 416
2021
Q2 		$68.6M Sell
2,242,669
-417,038
-16% -$12M 0.06% 401
2021
Q1 		$81M Sell
2,659,707
-555,742
-17% -$15.8M 0.08% 306
2020
Q4 		$63.6M Sell
3,215,449
-197,964
-6% -$3.2M 0.06% 404
2020
Q3 		$44.5M Buy
3,413,413
+124,083
+4% +$1.57M 0.05% 459
2020
Q2 		$37.3M Buy
3,289,330
+609,172
+23% +$8.65M 0.04% 481
2020
Q1 		$38.4M Sell
2,680,158
-188,256
-7% -$3.98M 0.06% 357
2019
Q4 		$78.1M Buy
2,868,414
+364,645
+15% +$10M 0.09% 268
2019
Q3 		$71.7M Sell
2,503,769
-819,327
-25% -$23.9M 0.09% 270
2019
Q2 		$92.3M Sell
3,323,096
-523,346
-14% -$14.8M 0.12% 213
2019
Q1 		$128M Sell
3,846,442
-76,410
-2% -$2.33M 0.17% 138
2018
Q4 		$114M Buy
3,922,852
+29,874
+0.8% +$1.07M 0.16% 140
2018
Q3 		$179M Sell
3,892,978
-157,755
-4% -$7.01M 0.22% 88
2018
Q2 		$151M Sell
4,050,733
-132,682
-3% -$4.48M 0.2% 103
2018
Q1 		$124M Sell
4,183,415
-573,174
-12% -$19.4M 0.17% 135
2017
Q4 		$163M Sell
4,756,589
-109,314
-2% -$3.69M 0.23% 87
2017
Q3 		$176M Buy
4,865,903
+85,792
+2% +$2.45M 0.27% 73
2017
Q2 		$124M Buy
4,780,111
+582,862
+14% +$12.4M 0.2% 103
2017
Q1 		$80.6M Buy
4,197,249
+1,427,127
+52% +$25.3M 0.14% 164
2016
Q4 		$46.2M Buy
2,770,122
+546,837
+25% +$9.89M 0.08% 324
2016
Q3 		$45.8M Sell
2,223,285
-681,192
-23% -$17.3M 0.08% 302
2016
Q2 		$88.9M Sell
2,904,477
-23,667
-0.8% -$822K 0.16% 137
2016
Q1 		$110M Buy
2,928,144
+448,985
+18% +$16.9M 0.2% 109
2015
Q4 		$107M Buy
2,479,159
+401,917
+19% +$17M 0.16% 147
2015
Q3 		$77.9M Buy
2,077,242
+486,307
+31% +$17.3M 0.11% 210
2015
Q2 		$54.1M Buy
1,590,935
+138,426
+10% +$4.71M 0.08% 302
2015
Q1 		$51.4M Sell
1,452,509
-69,650
-5% -$2.49M 0.08% 294
2014
Q4 		$51.8M Buy
1,522,159
+13,856
+0.9% +$492K 0.07% 345
2014
Q3 		$58.2M Buy
1,508,303
+710,396
+89% +$26.5M 0.08% 300
2014
Q2 		$31.1M Buy
797,907
+720,540
+931% +$26.8M 0.04% 476
2014
Q1 		$2.65M Sell
77,367
-244,313
-76% -$7.57M ﹤0.01% 2108
2013
Q4 		$6.75M Buy
321,680
+84,978
+36% +$2.15M 0.01% 1440
2013
Q3 		$5.56M Sell
236,702
-948,399
-80% -$26.9M 0.01% 1496
2013
Q2 		$31.8M Buy
+1,185,101
New +$34.3M 0.06% 354

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's MYGN Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Myriad Genetics (MYGN) stake by 0.12% in Q1 2026, selling an estimated $28.5K and leaving 4,499,724 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #1139.

D.E. Shaw & Co first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $179M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • D.E. Shaw & Co held 4,499,724 shares of Myriad Genetics worth $20.2M as of Q1 2026.
  • D.E. Shaw & Co sold 5,469 Myriad Genetics shares in Q1 2026, an estimated $28.5K.
  • Myriad Genetics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1139 holding.
  • D.E. Shaw & Co first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Myriad Genetics position peaked at $179M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.